Bevasiranib goes up against Lucentis

Article

Opko Health has initiated the Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (AMD).

Opko Health has initiated the Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (AMD).

The multinational trial aims to enrol more than 330 wet AMD patients and will assess whether bevasiranib, administered every eight or 12 weeks, is safe and whether it has equivalent efficacy to Lucentis (ranibizumab; Novartis), in preventing vision loss.

Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is the first therapy, based on the Nobel Prize-winning RNA interference technology, to advance to Phase III clinical trials.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
The logo for Eye2Gene, an artificial-intelligence powered ophthalmology diagnostic platform for inherited retinal disease, shows DNA helix imagery and an eye. Image credit: Heidelberg Engineering

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern
July 18th 2025
Article

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A very young child sits in a car seat while an adult smokes a cigarette near them. Concept image for secondhand smoke, exposure to smoking and early onset myopia development and progression in children. Image credit: ©New Africa – stock.adobe.com

Secondhand smoke is environmental risk factor in myopia development, study suggests

Lynda Charters
July 16th 2025
Article

The researchers shared the first cohort study established in China that examines the relationship between secondhand smoke and early onset of myopia

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Lynda Charters
July 13th 2025
Article
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Jordana Joy
July 12th 2025
Article

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

© 2025 MJH Life Sciences

All rights reserved.